Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2019 | Overcoming challenges in PCNCL treatment

Andrés Ferreri • 2 Jun 2019
ASCO 2019
Lymphoma Non-Hodgkin Lymphoma

Andrés Ferreri, MD, of the IRCCS San Raffaele Hospital, Milan, Italy, discusses the challenges and strategies to improve primary central nervous system (PCSNL) treatment viability. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Andrés Ferreri

Looking to the future of CNS lymphoma management 1:36
Looking to the future of CNS lymphoma management
Andrés Ferreri • 28 Feb 2025
Unmet clinical needs in CNS lymphomas: older patients and chemorefractory disease 1:49
Unmet clinical needs in CNS lymphomas: older patients and chemorefractory disease
Andrés Ferreri • 28 Feb 2025
The management and subgrouping of CNS lymphomas 3:33
The management and subgrouping of CNS lymphomas
Andrés Ferreri • 28 Feb 2025
IELSG32 trial: 88-month follow-up on MATRIX followed by auto-SCT in primary CNS lymphoma 7:00
IELSG32 trial: 88-month follow-up on MATRIX followed by auto-SCT in primary CNS lymphoma
Andrés Ferreri • 9 Jun 2021

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals